Amyotrophic lateral sclerosis (ALS) - Links to scientific articles about cyclosporin and ALS


1. Karlsson J, Fong KS, Hansson MJ, Elmer E, Csiszar K, Keep MF.
Life span extension and reduced neuronal death after weekly intraventricular cyclosporin injections in the G93A transgenic mouse model of amyotrophic lateral sclerosis. J Neurosurg. 2004 Jul;101(1):128-37.

2. Kirkinezos IG, Hernandez D, Bradley WG, Moraes CT.
An ALS mouse model with a permeable blood-brain barrier benefits from systemic cyclosporine A treatment. J Neurochem. 2004 Feb;88(4):821-6.

3. Pong K, Zaleska MM. Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases. Curr Drug Targets CNS Neurol Disord. 2003 Dec;2(6):349-56.

4. Avramut M, Achim CL. Immunophilins in nervous system degeneration and regeneration. Curr Top Med Chem. 2003;3(12):1376-82.

5. Iwasaki Y, Ichikawa Y, Igarashi O, Iwamoto K, Kinoshitata M, Ikeda K.
Neuroprotective actions of FK506 and cyclosporin A on motor neuron survival following neonatal axotomy. Neurol Res. 2002 Sep;24(6):573-6.

6. Shefner JM, Brown RH Jr, Cole D, Chaturvedi P, Schoenfeld D, Pastuszak K, Matthews R, Upton-Rice M, Cudkowicz ME. Effect of neurophilin ligands on motor units in mice with SOD1 ALS mutations. Neurology 2001 Nov 27;57(10):1857-61.

7. Anneser JM, Gmerek A, Gerkrath J, Borasio GD, Heumann R. Immunosuppressant FK506 does not exert beneficial effects in symptomatic G93A superoxide dismutase-1 transgenic mice. Neuroreport 2001 Aug 28;12(12):2663-5.

8. Keep M, Elmer E, Fong KS, Csiszar K. Intrathecal cyclosporin prolongs survival of late-stage ALS mice. Brain Res 2001 Mar 16;894(2):327-31.

Close Menu